AbbVie has placed a high price on that potential, coughing up $700 million for a phase 1 candidate and offering up to $1.225 ...

AbbVie has a lofty goal for 2025 — and a big move in cancer treatment could stoke beleaguered AbbVie stock. Investor's Business Daily. AbbVie Takes On Pfizer And Merck With Its Next Leg Of Growth.

4. Humira is AbbVie’s flagship product. The drug accounts for more than 60 percent of the company’s total sales. AbbVie believes Humira will approach $21 billion in sales in 2020. 5. By reaching the ...

Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...